Latest Articles

Publication Date
NET-DNA Activates the ANXA2/TMEM215/BiP Axis to Promote Mitophagy-Mediated Anoikis Resistance in Endometriosis.

Endometriosis (EMs) features ectopic implantation of endometrial stromal cells (EESCs) and strong anoikis resistance, yet how inflammatory signals reprogram mitochondrial function remains unclear. Here, neutrophil extracellular traps (NETs), particularly their …

Published: April 27, 2026, midnight
Detection of Activin A and Follistatin as Potential Biomarkers in Women with Ovarian Endometriosis.

Endometriosis is a condition characterized by the growth of tissue similar to the uterine lining outside the uterus. This study aimed to evaluate certain sex hormones and determine the levels …

Published: April 24, 2026, midnight
Electrospun Cellulose Acetate Nanofibers for Healthcare Products: Towards Sensing Pads for Endometriosis.

The need for reliable preventive medicine tools is growing, especially for diseases with long diagnostic delays, such as endometriosis, which can take several years to diagnose. In this context, cellulose …

Published: April 24, 2026, midnight
Ep. 6 - The Invisible Illness Impacting Millions of Women - dailywire.com

Ep. 6 - The Invisible Illness Impacting Millions of Women dailywire.com

Published: April 18, 2026, 5:02 p.m.
Medicus Pharma Showcases Long-Acting Teverelix Data, Targets Precision Endometriosis Therapy - TipRanks

Medicus Pharma Showcases Long-Acting Teverelix Data, Targets Precision Endometriosis Therapy TipRanks

Published: April 15, 2026, 1:38 p.m.
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression - The Manila Times

Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression The Manila Times

Published: April 15, 2026, 11:45 a.m.
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression - GlobeNewswire

Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression GlobeNewswire

Published: April 15, 2026, 11:30 a.m.
Pathogenesis of Adenomyosis: An Integrated Review of Cellular Origins, Molecular Mechanisms, and Intersecting Diseases.

Adenomyosis is a prevalent disorder of the archimetra, historically conflated with endometriosis but possessing a unique pathobiological trajectory. This review synthesises current molecular evidence to propose a unified mechanistic framework …

Published: April 14, 2026, midnight
Expression and Function of Meflin in Human Endometrial Decidualization.

Decidualization of endometrial stromal cells involves significant morphological and functional changes in which alpha-smooth muscle actin (αSMA) expression decreases. Meflin, a glycosylphosphatidylinositol-anchored protein, suppresses αSMA expression and inhibits fibrosis in …

Published: April 4, 2026, midnight
Single-Dose Bioequivalence Study of Elagolix Tablets 200 mg (Test Product) and Elagolix Tablets 200 mg (Reference Product) in Healthy Non-Pregnant, Non-Lactating Premenopausal Female Subjects Under Fasting Conditions.

Elagolix is a short-acting oral gonadotropin-releasing hormone antagonist utilized for treating endometriosis-associated pain by rapidly suppressing gonadotropins and estradiol. Although well characterized in Western populations, clinical data regarding its use …

Published: April 2, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!